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Abstract
Mycoses summarized in the hyalohyphomycosis group are heterogeneous, deﬁned by the presence of hyaline (non-dematiaceous) hyphae.
The number of organisms implicated in hyalohyphomycosis is increasing and the most clinically important species belong to the genera
Fusarium, Scedosporium, Acremonium, Scopulariopsis, Purpureocillium and Paecilomyces. Severely immunocompromised patients are particularly
vulnerable to infection, and clinical manifestations range from colonization to chronic localized lesions to acute invasive and/or disseminated
diseases. Diagnosis usually requires isolation and identiﬁcation of the infecting pathogen. A poor prognosis is associated with fusariosis and
early therapy of localized disease is important to prevent progression to a more aggressive or disseminated infection. Therapy should
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include voriconazole and surgical debridement where possible or posaconazole as salvage treatment. Voriconazole represents the ﬁrst-line
treatment of infections due to members of the genus Scedosporium. For Acremonium spp., Scopulariopsis spp., Purpureocillium spp. and
Paecilomyces spp. the optimal antifungal treatment has not been established. Management usually consists of surgery and antifungal
treatment, depending on the clinical presentation.
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Background
The frequency and diversity of serious fungal infections is
increasing [1–3]. Severely immunocompromised patients are
particularly vulnerable to infection from unusual moulds and
yeasts, which are present in the environment. Clinical
manifestations range from colonization to chronic localized
lesions to acute invasive and/or disseminated diseases.
Localized infections may occur following penetrating trauma
in healthy individuals; dissemination usually occurs among
immunocompromised patients and the outcome is closely
related to the degree and persistence of immunosuppression
[4]. Diagnosis usually requires isolation and identiﬁcation of
the infecting pathogen; however, serology, imaging tech-
niques and clinical manifestations are not speciﬁc, and
pan-fungal and species-speciﬁc PCR are useful investigational
tools. Many of the emerging opportunistic moulds demon-
strate in vitro and in vivo resistance to various antifungals. As
a result, successful treatment may require adjunctive surgical
debridement and, when possible, reconstitution of the host
immune system.
Mycoses in the hyalohyphomycosis group are heteroge-
neous, deﬁned by the presence of hyaline hyphae in tissues
[3,5]. The number of organisms causing hyalohyphomycosis
is increasing and the most clinically important genera are
Fusarium spp., Scedosporium spp., Acremonium spp., Scopular-
iopsis spp., Purpureocillium and Paecilomyces spp. [3,6–9].
Table 1 displays an overall summary of the in vitro
antifungal susceptibility for selected fungi. Table 2 gives an
overview of antifungals and dosages for adults and
paediatric patients.
The executive board of the European Fungal Infection Study
Group (EFISG) of the European Society of Clinical Microbi-
ology and Infectious Diseases (ESCMID) and the European
Confederation of Medical Mycology (ECMM) decided to
proceed with a pan-European guideline for the diagnosis and
management of hyalohyphomycosis. Participants were chosen
on the basis of their expertise in the ﬁeld of medical mycology
and for further proﬁciency, EFISG and ECMM set up group
TABLE 1. Overview of possible in vitro antifungal susceptibility patterns for selected hyalohyphomycetes
Pathogen AMB Flucytosine Echinocandins Fluconazole Itraconazole Voriconazole Posaconazole
Fusarium solani I-R R R R R S-I-R S-I-R
Scedosporium apiospermum I-R R S I-R S-R S S
Scedosporium boydii I-R R S I-R S-R S S
Scedosporium aurantiacum R NT R NT R S S-R
Scedosporium proliﬁcans R R S-I-R R R R R
Paecilomyces species S I R R S I-S S
Purpureocillium liliacinum R R R R S S S
Acremonium species S-R R R R S-R S-R S-R
Scopulariopsis species I-R R NT R R R I-R
The classiﬁcations here (S, I, R) only indicate a gross guide, deviations may occur. Susceptibility testing gives an overview of drug activity and therefore may support choice of
antifungals.
Combinations of MIC data are not shown.
Data are collected from references [47–51,125,155–157,162,181–185].
AMB, amphotericin B and its lipid formulations; S, susceptible; I, intermediate; R, resistant; NT, not tested.
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coordinators for each thematic allocation to provide and
present the results of the discussion of subgroups to the
complete guideline development group. The subgroups were
set up according to the content-related topics fusariosis,
scedosporiosis and others (Paecilomyces, Purpureocillium, Acre-
monium and Scopulariopsis infections): the fungal pathogen,
clinical spectrum, diagnosis and therapy. The manuscript was
drafted by the subgroup coordinators Marianna Tortorano,
Clinical Microbiologist (CM) with a strong expertise in
diagnosing fungal infections and fungal identiﬁcation, Malcolm
Richardson, CM with specialization in general medical mycol-
ogy, Emmanuel Roilides, Infectious Diseases doctor (ID) with
intense expertise in the management of fungal infections in
immunocompromised patients, Anne von Diepingen, Molecular
Microbiologist with a focus on fungal typing methods, Patrizia
Munoz, ID with broad expertise in clinical mycology, Elisabeth
Johnson, Joseph Meletiadis and Paul Verweij, CMs with a strong
focus on diagnosing fungal infections, identiﬁcation of patho-
genic fungi and antifungal susceptibility testing, Thomas Frei-
berger, CM representing an expert in immunology and
molecular-based techniques and Cornelia Lass-Flo¨rl, CM with
expertise in diagnosing fungal infections. The complete guideline
development group includes 37 individuals from all relevant
professionals (e.g. intensive care units, fungal taxonomy,
molecular-based techniques) and different geographical regions
to ensure broad coverage of the different domains dealt with by
the work presented herein. The detailed expert input is given in
the author contribution section.
Guideline Approach
The overall aim of this guidance is to address the difﬁculties in
managing and diagnosing invasive fungal infections due to
hyalohyphomycetes.
The objectives of the guidelines are to:
 Recommend approaches and practical tools for education
and training of healthcare professionals in managing invasive
fungal infections due to hyalophyphomycetes.
 Present practical considerations that should be taken into
account when dealing with fungal infections.
The guideline covers epidemiology, clinical spectrum,
diagnosis and therapy, mainly for species associated with
the genera Fusarium and Scedosporium. The guidelines pre-
sented herein are limited to invasive infections caused by
these fungi. For diagnosis and treatment recommendations,
tables list the scientiﬁc evidence. Recommendations for
various patients at risk are weighted differently based on
available literature.
Methods for Literature Search
Main keywords/MeSH terms were retrieved from reviews on
hyalohyphomycoses and were deﬁned by separate search
strings according to the different topics (e.g. Fusarium AND/
OR fusariosis). Systematic literature searches in the Medline
TABLE 2. Adult and paediatrica dosages of systemic antifungal agents
Agent
Daily dosage per age group
>18 years 13–18 years 2–12 years 1–24 months Neonates
Amphotericin B deoxycholateb 1–1.5 mg/kg QD 1–1.5 mg/kg QD 1–1.5 mg/kg QD 1–1.5 mg/kg QD 1–1.5 mg/kg QD
Liposomal amphotericin Bb 3 (5) mg/kg QD 3 (5) mg/kg QD 3 (5) mg/kg QD 3 (5) mg/kg QD 3 (5) mg/kg QD
Amphotericin B lipid complex 5 mg/kg QD 5 mg/kg QD 5 mg/kg QD 5 mg/kg QD 5 mg/kg QD
Amphotericin B colloidal
dispersion
3–4 mg/kg QD 3–4 mg/kg QD 3–4 mg/kg QD 3–4 mg/kg QD n/a
Itraconazole IV 200 mg BID (for 2 days),
followed by 200 mg daily
n/a n/a n/a n/a
Itraconazole oral suspension/
capsulesc
600 mg/day (for 3 days),
followed 400 mg/day
2.5 mg/kg BID 2.5 mg/kg BID n/a n/a
Voriconazole IVc 6 mg/KG IV q 12 h on
day 1 4 mg/kg BID
4 mg/kg BID 8 mg/kg BID n/a n/a
Voriconazole oral suspension/
capsulesc
200 mg BID 200 mg BID 9 mg/kg BID
(max: 350 mg BID)
n/a n/a
Posaconazolec 200 mg QID or 400 mg BID 200 mg QID or
400 mg BID*
n/a n/a n/a
Caspofungin 50 mg/day (day 1: 70 mg) IV 50 mg/m2 (day 1: 70)
IV (max: 70)
50 mg/m2 (day 1: 70)
IV (max: 70)
50 mg/m2 (day 1: 70) IV 25 mg/m2
Anidulafungin 100 mg (day 1: 200 mg) IV
Micafungin 100 mg/day 100 mg/m2 >40 kg: 100 mg/day >40 kg: 100 mg/day >40 kg: 100 mg/day
<40 kg: 2–4 mg/kg/day <40 kg: 2–4 mg/kg/day <40 kg: 2–4 mg/kg/day
QD, once a day; BID, twice a day; QID, four times a day; IV, intravenous; PO, oral; n/a, no or no sufﬁcient data.
aEuropean Society of Clinical Microbiology and Infectious Diseases (ESCMID) guildelines for the diagnosis and management of Candida diseases 2012: prevention and management
of invasive infections in neonates and children caused Candida spp. [186].
bDue to toxicity reasons we recommend the usage of lipid amphotericin B instead of amphotericin B deoxycholate.
cTherapeutic drug monitoring is recommended if itraconazole, voriconazole or posaconazole is prescribed; monitoring is highly recommended in unsatisfactory response
to therapy, suspicion of toxicity or drug interactions, impaired liver or renal function and also in patients on extracorporal membrane oxygenation (ECMO) [187–189].
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database, using PubMed, and the Cochrane Database, were
performed. Our research was limited to the period 1984–
2012, abstracts and unpublished studies as well as studies
written in a language other than English were excluded. No
studies were excluded a priori for weakness of design or data
quality. For further proﬁciency, a group coordinator of each
subgroup (Fusarium and fusariosis, Scedosporium and scedos-
poriosis and others) was nominated to provide and present
the results of the discussion of this subgroup to the plenary
sessions. The subgroups were set up by EFISG and ESCMID.
The expert group reviewed all the available literature and
documents and views were shared by email, teleconferences
and face-to face meetings during 2012–2013. Once a ﬁrst
consensus was reached, the preliminary recommendations
were presented to the whole group and discussed, developed
further and ﬁnalized as a group consensus.
Grading Criteria of Evidence
The appraisal of the available evidence was performed
following the same lines of reasoning used in the previously
developed guidelines for the management of Candida infections
[10]. Studies were evaluated according to their design as well
as their potential bias or validity, to deﬁne the strength of
evidence they provided. A checklist for the critical appraisal of
each selected publication was used to assess the validity of
selected studies, the deﬁnition of the strength of recommen-
dations and their level of evidence were summarized using
criteria described in Table 3.
Certain recommendations were originally controversial
(e.g. the need for susceptibility testing in rare fungi to guide
antifungal treatment), a majority vote was a necessity to
formulate a recommendation. The guideline follows the
principles of the ‘Grades of Recommendations, Assessment,
Development and Evaluation’ (GRADE) [11]. These guidelines
also adopted the ‘Appraisal of Guidelines, Research and
Evaluation’ (AGREE) items for the development of guidelines
and all domains of AGREE were addressed [12].
Fusariosis
The genus Fusarium contains mainly saprophytes and plant
pathogens; only a few species cause infections in humans [2].
Among these are the species complexes encompassing Fusa-
rium solani, Fusarium oxysporum, Fusarium verticillioides (including
the obsolete species Fusarium moniliforme) and Fusarium
proliferatum—the latter two are part of the Fusarium (Gibber-
ella) fujikuroi species complex [13–18], which present the most
commonly found opportunistic pathogenic species. In contrast,
Fusarium chlamydosporum, Fusarium anthophilum, Fusarium dime-
rum, Fusarium subglutinans and Fusarium sacchari have been
occasionally implicated in human diseases [13–18]. The most
pathogenic species are found within the F. solani species
complex [19], which include Fusarium falciforme (formerly
known as Acremonium falciforme) and Fusarium lichenicola
(formerly known as Cylindrocarpon lichenicola).
Opportunistic human pathogens of the genus Fusarium
cause a broad spectrum of infections predominantly in
immunocompromised individuals ranging from superﬁcial,
locally invasive to disseminated infections. Direct inoculation
and airborne uptake are the most common routes of infections
[20]. The clinical manifestation of fusariosis depends largely on
the immune status of the host and the portal of entry [2],
which include paranasal sinuses, lungs and skin. Neutropenia is
one of the most important risk factors for acquiring dissem-
inated fusariosis. Disseminated infections occur mainly in
patients with haematological malignancies and in haematopoi-
etic stem cell transplant recipients [21] and the incidence
varies in different geographic regions. For example, in Brazil it
was recently reported as the leading invasive fungal disease
followed by aspergillosis and invasive candidosis [1].
Clinical Spectrum
The typical manifestation of fusariosis in the immunocompro-
mised population is invasive disease, often with haematoge-
nous dissemination [22]. In patients with underlying
TABLE 3. Strength of the European Fungal Infection Study
Group of the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) and European Confederation
of Medical Mycology (ECMM) recommendation and quality of
evidence
Strength of a recommendation (SoR)
Grade A ESCMID and ECMM strongly support a recommendation for use
Grade B ESCMID and ECMM moderately support a recommendation for use
Grade C ESCMID and ECMM marginally support a recommendation for use
Grade D ESCMID and ECMM support a recommendation against use
Quality of evidence (QoE)
Level I Evidence from at least one properly designed randomized
controlled trial
Level II* Evidence from at least one well-designed clinical trial, without
randomization; from cohort or case–controlled analytical studies
(preferably from more than one centre); from multiple time series;
or from dramatic results of uncontrolled experiments
Level III Evidence from opinions of respected authorities, based on clinical
experience, descriptive case studies, or reports of expert
committees
*Added index:
r: Meta-analysis or systematic review of randomized controlled trials.
t: Transferred evidence, that is, results from different patients’ cohorts, or similar
immune-status situation.
h: Comparator group is a historical control.
u: Uncontrolled trial.
a: Published abstract (presented at an international symposium or meeting).
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haematological diseases, infections occur most frequently in
neutropenic patients with acute leukaemia, particularly acute
myeloid leukaemia [4]. The features of patients with dissem-
inated infection are similar in many respects to those of
patients with disseminated aspergillosis [3,14]. Invasive Fusari-
um infection often involves skin as well as lung or sinus lesions
[11] and usually can be isolated from blood cultures in up to
40–60% [3,14]. Skin lesions caused by Fusarium appear in 60–
80% of the patients. They include erythematous macula or
papula, are usually indurated and painful with a central area of
necrosis. The mortality attributable to Fusarium infections in
immunocompromised patients ranges from 50% to 70%
[2,14,23,24]. Persistence of severe immunosuppression and
particularly neutropenia is the most important factor associ-
ated with the poor outcome of patients with invasive fusariosis
[4,21,25].
Diagnosis
Radiological ﬁndings of pulmonary Fusarium infections are
suggestive of angioinvasion [26,27]. Chest radiographs showed
non-speciﬁc ﬁndings in 30% and in chest computed tomogra-
phy (CT) scans nodules or masses were the most common
ﬁndings with a halo sign being absent in 80% of patients
investigated [26,27]. A CT scan is more sensitive (AII) than a
chest X-ray [26] and therefore is the method of choice in
imaging procedures. The deﬁnitive diagnosis requires isolation
of Fusarium spp. from infected sites (skin, sinuses, lungs, blood
or others) [22] (AIII), see Table 4. These fungi may invade
blood vessels and histopathological ﬁndings include acute
branching septate hyaline hyphae with optional sporulation,
resulting in haematogenous spread. Culture identiﬁcation is
important because of the histopathological similarities
between Fusarium and other hyalohyphomycetes. Although
the genus Fusarium can be identiﬁed by culture by the
production of hyaline, crescent or banana-shaped, multicellular
macroconidia, species identiﬁcation is difﬁcult and may require
molecular methods. Molecular-based identiﬁcation systems
based on multilocus sequence typing methodology [28],
genus-speciﬁc PCR and 28s rRNA gene sequencing [29],
multiplex tandem PCR [30], multiplex suspension array [31,32]
and the commercially available DiversiLab system [33], which
uses automated repetitive sequence-based PCR (rep-PCR) and
web-based data analyses, appear promising, but have as yet not
been fully evaluated for the routine diagnostic setting. Species
identiﬁcation by matrix-assisted laser desorption ionization
time-of-ﬂight mass spectrometry also appears promising, but
remains to be formally standardized and validated [34,35]
(CIII).
Several developed in-house PCR assays (pan-fungal quanti-
tative PCR screening tests, pan-fungal semi-nested PCR
followed by fragment length analysis or sequencing, multiplex
PCR, nested PCR, speciﬁc PCR and duplex quantitative PCR)
have been applied to the direct diagnosis of Fusarium infection
with varying speciﬁcity and sensitivity [36–43]. Molecular tests
may be helpful, but should be used only to supplement
conventional laboratory tests (CIII).
The b1,3-D-glucan test is usually positive in patients suffering
from invasive Fusarium infections [43] (BIII). However, the test
is not able to distinguish Fusarium from many other agents
of fungal infection, e.g. Candida spp., Aspergillus spp. and
TABLE 4. Summary of recommendations for diagnosis of Fusarium infection
Fusarium infection/
Population Test SoR QoE Comment References
Any population Direct microscopy A III Essential investigation [2]
Culture (species
identiﬁcation)
A III Essential investigation
Easily recovered on routine mycological media without cycloheximide
Accurate species assignment is important for guiding clinical management
[2,190]
Histopathology A IIu Essential investigation
Features of hyaline septate hyphae (with acute angle branching) are similar
to those seen with aspergillosis
[120]
Immunohistochemistry C III Not yet evaluated [120]
b-D-Glucan test/
Galactomannan
B III Glucan usually positive in case of invasive fusariosis. Aspergillus galactomannan
sometimes positive in patients with fusariosis
[46]
Pan-fungal PCRs for
identiﬁcationa
C II In combination with conventional methods
High negative predictive values
[36–38]
Multiplex PCRsa C III Not yet validated
Cover limited number of species/genera
[30,37,39]
In situ hybridization C III Not yet evaluated
In-house tests
[191,192]
Susceptibility testing C III Gives an overview of drug activity and may be helpful in selecting antifungals [2,181,182,193–195]
Environmental sampling
(and fungal typing)
A III In case of an outbreak situation [33,76]
Haematological
patients
Chest computed
tomography (CT) scan
A IIu None of patients had normal CT
Pulmonary nodules in 82% of patients
[26]
QoE, quality of evidence; SoR, strength of recommendation.
aThird-party appraisal of results and harmonization of PCR-based techniques are necessary before any clear recommendations can be made regarding clinical utility.
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Trichosporon spp. [44,45]. The Aspergillus galactomannan test
may also produce positive results in approximately half of
patients suffering from fusariosis [46].
Antifungal susceptibility testing is recommended (CIII) for
epidemiological reasons and under certain circumstances to
guide antifungal therapy. However, clinical breakpoints need to
be deﬁned, and in vitro and in vivo correlation may be absent.
Fusarium spp. may display resistance towards numerous
antifungal agents (Table 1), with F. solani complex frequently
showing pan-azole resistance. Other species show a wide
range of MICs when tested against voriconazole, posaconazole
and amphotericin B [18,47–55].
Therapy
Due to the lack of clinical trials and the critical role of immune
reconstitution in the outcome of fusariosis, the optimal
treatment strategy for patients with severe Fusarium infection
remains unclear. Reversal of immunosuppression is recom-
mended (AIII) [1,21] whenever possible.
Early therapy of localized disease is important to prevent
progression to a more aggressive or disseminated infection
(AII). This therapy should include surgical debridement and
systemic antifungal therapy [2,14,56–59].
In immunocompromised patients, voriconazole, amphoter-
icin B deoxycholate, lipid-based amphotericin B formulations
and various combinations have been reported with varying
success (Table 5). Based on the data available, we recommend
voriconazole (AII) and lipid-based amphotericin B formulations
(BIIt,r). Lipid-based amphotericin B preparations exhibit fewer
side-effects when compared with amphotericin B deoxycholate
and should be favoured. The response rate to a lipid
formulation of amphotericin B appeared superior to that of
deoxycholate amphotericin B [4]. Posaconazole is recom-
mended as salvage therapy (AII) [23,60–62]. Data on combi-
nation therapy for fusariosis are limited to a few case reports
(CIII); caspofungin plus amphotericin B deoxycholate [63],
amphotericin B deoxycholate plus voriconazole [64–66],
amphotericin B deoxycholate plus terbinaﬁne [67] and voric-
onazole plus terbinaﬁne [68] have been reported.
In addition to antifungal treatment, the optimal management
of patients with fusariosis includes surgical debridement of
infected tissues (AIII) [58], removal of venous catheters in
conﬁrmed catheter-related fusariosis and reversal of the
immunocompromised state (AII) (Table 6) [69]. The role of
granulocyte colony-stimulating factor or granulocyte–macro-
phage colony-stimulating factor in the adjuvant treatment of
fusariosis is not established. Few cases report successful
treatment of invasive fusariosis with a combination of antifun-
gal and such adjuvant treatment [70–73] (CIII) (Table 6).
Because of the risk of relapse in immunosuppressed patients
with prior fusarial infections [4], secondary prophylaxis should
be considered (voriconazole, posaconazole, amphotericin B
lipid formulation) (AIII) [4,74]. Consideration should be given
to postponing cytotoxic therapy or using granulocyte col-
ony-stimulating factor to shorten the period of neutropenia. A
thorough evaluation and treatment of skin lesions should be
undertaken before antineoplastic therapy [22]. The skin may
be the primary source of these life-threatening infections.
Prevention of Hospital-Acquired Infection
Airborne fusariosis is thought to be acquired by inhalation of
airborne conidia [20]. In severely immunocompromised
patients, every effort should be made to protect the patient
from exposure to the pathogen [75] (AII). Fusarium reservoirs
TABLE 5. Summary of recommendations for treatment of Fusarium infection
Population Intention SoR QoE Comment References
Immunocompromised
patients
First-line treatment
Voriconazole A IIt,r Therapeutic drug monitoring required
Response rate was associated with underlying
condition and infection site
[23,24,60,196,197]
Liposomal amphotericin B B IIt,r Fungi may be resistant to amphotericin B [4,198,199]
Amphotericin B lipid complex C III Limited case reports [200]
Amphotericin B deoxycholate D IIt,u Fungi often resistant to amphotericin B
Breakthrough infections may occur
Excessive toxicity
[4,198,199]
Any echinocandin D III Intrinsically resistant [21]
Any combination therapy C III Limited reports
Combination not better than voriconazole alone
[23,24,63–65,67,68,196]
Salvage treatment
Posaconazole A II Overall success rate 50%
Breakthrough infections
Therapeutic drug monitoring required
[23,61]
Voriconazole A III Substantial efﬁcacy
Therapeutic drug monitoring required
[62]
QoE, quality of evidence; SoR, strength of recommendation.
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include tap water [76], sinks [77] and other wet areas such as
showers and steam baths [75]. For outbreak control, identi-
fying the source of infection is essential (AII), see Table 4.
There have also been cases where onychomycosis has been
the source of a subsequent disseminated infection in an
immunocompromised patient [78]. Careful evaluation for
onychomycosis and removal of the focus is mandatory in
those known to be or likely to become immunocompromised.
Scedosporiosis
Scedosporium spp. are commonly isolated from rural soils,
polluted waters, composts and from manure of cattle and fowl.
As with Fusarium, members of the genus Scedosporium are
saprophytes that mainly cause opportunistic infections in
immunocompromised patients [79]. However, disseminated
infections—often with central nervous system involvement—
can follow near drowning accidents in previously healthy
individuals [80–83]. Scedosporium infections are caused mainly
by Scedosporium boydii (teleomorphic state, Pseudallescheria
boydii), Scedosporium apiospermium (teleomorphic state, Pseud-
allescheria apiosperma), Scedosporium aurantiacum and Scedos-
porium proliﬁcans. While S. aurantiacum and S. proliﬁcans are
predominant in hot and arid countries such as Spain and
Australia, S. boydii and S. apiosperma are predominant in
temperate areas such as central Europe. In general, all
Scedosporium spp. are cosmopolitan, being ubiquitously present
in the environment. They cause a wide spectrum of infections
ranging from classical subcutaneous infections, like mycetoma
with spread via the lymphatic system, to disseminated infec-
tions with central nervous system involvement [84–86]. These
moulds are in particular known for their special neurotropic
nature and their high rate of therapeutic failures and relapses
[87]. In particular, S. proliﬁcans represents a pan-antifun-
gal-resistant species with mortality rates of up to 95% in
immunocompromised patients [88]. Scedosporium proliﬁcans
grows greyish-white, to olive-grey to black and therefore in
proper meaning is excluded from the hyalohyphomycetes; for
the sake of simplicity and because they phylogenetically belong
to the Scedosporium species complex, S. proliﬁcans is dealt with
herein.
Clinical Presentation
The clinical spectrum of infection in immunocompetent hosts
includes keratitis, endophthalmitis, otitis, sinusitis, central
nervous system infections, osteoarticular and soft tissue
infections and pneumonia after near drowning [89–95]. In
the setting of severe immunosuppression, deep-seated infec-
tions can involve any organ with a predilection for skin,
sinuses, lungs and central nervous system [6,80,81,84,91,96–
106]. In healthy individuals cerebral infection is secondary to
contiguous spread from sinuses [107], penetrating trauma [89]
or pulmonary infection following near drowning in polluted
water [108,109]. In immunocompromised patients including
those after lung transplantation, central nervous system
infections tend to occur following haematogenous dissemina-
tion [80–83,91]. Patients with cystic ﬁbrosis may be either
colonized or suffering from lung infection [110–112]. Delayed
treatment of brain abscesses due to P. boydii is associated with
a high mortality rate (>75%) [106,108,113].
Diagnosis
Few imaging descriptions have been reported and the radio-
graphic ﬁndings of pulmonary infections show multiple bilateral
patchy nodular condensations, alveolar inﬁltrates or, most
commonly, consolidation without cavitation [114–116]. The
rapid and fatal evolution of S. proliﬁcans could account for the
lack of cavities or crescent signs [117]. Laboratory diagnosis
(Table 7) includes conventional methods such as culture,
direct microscopy and histopathology (AIII). Histopathological
ﬁndings of septate, branching, hyaline hyphae are similar to
those of aspergillosis, although sometimes annelloconidia
(conidia that develop from the extruded end of a conidio-
phore) may be seen in tissue sections [97,118–120]. Similarly
to Fusarium, blood cultures may be positive in >50% of
TABLE 6. Summary of recommendations for Fusarium disease and adjunctive treatment
Population Intention SoR QoE Comment References
Haematological, cancer and
neutropenic patients
Granulocyte transfusion (be cautious if
allogeneic HSCT is indicated)
C III Limited number of patients Resolution in patients
who recovered from myelosuppression
[14]
[71–73]
Acute leukaemia Surgical debridement (localized infection) A IIt Successful outcome [58]
Bone marrow transplant
patients
Surgical debridement (localized infection) A IIt Independent protective factor [59]
Any population Surgical debridement A III Solitary pulmonary nodules
Aggressive surgical debridement of nectrotic tissue
Independent protective factor
[2,201–205]
HSCT, haematopoietic stem cell transplant; QoE, quality of evidence; SoR, strength of recommendation.
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S. proliﬁcans infections as a result of its ability to sporulate in
tissue allowing haematogenous spread. A range of diagnostic
molecular methods have been employed but are not yet
validated and should be used only as an adjunct to conventional
laboratory tests (CIII).
Isolation of the fungus is important because of the variable
susceptibility of these fungi to amphotericin B and other
antifungal agents, especially recent triazoles (AIII). Molecu-
lar-based methods for identiﬁcation such as rolling circle
ampliﬁcation on cultures [121], ampliﬁed fragment length
polymorphism analysis [122], loop-mediated isothermal ampli-
ﬁcation PCR [123] and semi-automated repetitive sequence--
based PCR [124] appear promising, but have yet to be
evaluated in the routine clinical setting (CIII). Particularly
within the P. boydii complex, identiﬁcation is complicated by
low interspecies diversity and high intraspecies variability.
Therapy
Given the scarcity of data and the potential publication bias, no
solid recommendations can be provided. In vitro and in vivo data
show that P. apiospermum is resistant to amphotericin B and
ﬂucytosine and demonstrates variable susceptibility to itraco-
nazole, voriconazole, posaconazole and micafungin. Vorico-
nazole is the only compound with good activity in vitro against
S. aurantiacum [125], and S. proliﬁcans is resistant to caspofun-
gin, azoles and polyenes [48], see Table 1; voriconazole
demonstrated the strongest in vitro activity [126]. A recent
study suggests synergistic activity of the antibacterial agent
colistin with voriconazole against Scedosporium spp. [127].
The management of infections due to members of the genus
Scedosporium depends on the underlying condition of the host
and voriconazole represents the ﬁrst-line treatment (AII)
[96,99,100,114], see Table 8. Surgical resection remains the
key to a successful outcome if the lesions are localized (AIII).
The therapeutic outcome is usually poor in the setting of
persistent immunosuppression. A combination of interferon-c
and antifungal therapy in a patient with chronic granulomatous
disease helped to control disseminated infection [128]; how-
ever, due to the lack of additional data, no solid recommen-
dations can be provided.
The outcome of S. proliﬁcans infection is very poor, because
no drug appears to be effective [96,129], see Table 9. Surgical
debridement of infected tissue and recovery of immunosup-
pression appear to be the major means of halting progression
of the infection [105,130]. A few reports of successful
treatment with voriconazole plus terbinaﬁne have been
published [68,91,131–133], we moderately recommend this
combination (BII). Also, case series of S. apiospermum infec-
tions demonstrated efﬁcacy of combinations of azoles and
terbinaﬁne [134], sequential azole and terbinaﬁne [135], or
voriconazole and caspofungin [136]. The use of miltefosine as
an antifungal agent for severe infection with S. proliﬁcans needs
to be clariﬁed in detail, up to now only one case report is
available [111].
Indications for surgical removal of tissue infected with
Fusarium and Scedosporium species are given in Table 10.
Paecilomyces and Purpureocillium Infections
Until recently, the genus Paecilomyces harboured two known
human pathogenic species: Paecilomyces variotii and Paecilomyces
lilacinus. Luangsa-Ard et al. [137] revised the genus and the
latter species now ofﬁcially holds the name Purpureocillium
TABLE 7. Summary of recommendations for diagnosis of Scedosporium infections
Population Test SoR QoE Comment References
Any population Direct microscopy A III Essential investigation [85]
Culture (species identiﬁcation by morphology
and physiological characteristics)
A III Essential investigation Selective media supplemented with
cycloheximide or benomyl (10 mg/L, Sce– Sel+) allows growth
of Scedosporium over other ﬁlamentous fungi from bronchial
secretions.
[85,122,123,136,206–210]
Molecular-based identiﬁcation methods C III Accurate species assignment is important for guiding clinical
management
[121–123,211]
Histopathology A III Hyaline thin-walled septate hyphae, 2-5 lm wide similar to
those seen with aspergillosis and other hyalohyphomycoses
Irregular branching
[120,212,213]
Pan-fungal PCRa C III Molecular tests could be used in combination with conventional
laboratory tests.
[36–38]
Multiplex PCRa C III Molecular tests could be used in combination with conventional
laboratory tests.
[30,31,37,39]
In situ hybridization C III Low sensitivity
Not yet validated
[191,192]
Species identiﬁcation (MALDI TOF and PCR) C III Not yet validated [124,214–219]
Physiological typing C III In case of an outbreak situation [220]
In vitro susceptibility testing C III Gives an overview of drug activity and therefore may support
choice of antifungals
[221–223]
MALDI-TOF, matrix-assisted laser desorption ionization time-of-ﬂight mass spectrometry; QoE, quality of evidence; SoR, strength of recommendation.
aThird-party appraisal of results and harmonization of PCR-based techniques are necessary before any clear recommendations can be made regarding clinical utility.
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lilacinum. Both representatives are rarely pathogenic in humans
and are isolated from soil and decaying plant material [138–
141]. The deﬁnitive diagnosis requires isolation of the patho-
gens from infected sites. Disseminated infection, pneumonia,
cellulitis, fungaemia and pyelonephritis have been reported in
immunosuppressed patients [138–140,142–144], and cutane-
ous infection in an immunocompetent patient [145]. The
portal of entry involves breakdown of skin or mucous
membranes and inhalation. Infections associated with contam-
ination of ﬂuids and air conditioning systems have been
reported [141,146]. The optimal antifungal treatment has not
been established. Clinical management consists of antifungal
treatment (AIII), surgery (BIII) or a combination of both, see
Table 11. Usually, in vitro P. lilacinum are highly resistant to
amphotericin B but susceptible to azoles and P. variotii is
usually amphotericin B susceptible.
Acremonium Infections
Acremonium species are ubiquitous in the environment and
typically found in soil [8,147]. Recently, Summerbell et al. [148]
TABLE 8. Summary of recommendations for treatment of Scedosporium spp. infections
Population Intention SoR QoE Comment References
Immunocompromised patients First-line treatment
Voriconazole A IIr,t Therapeutic drug monitoring required
Success in 66%
[6,87,96,224–228]
Itraconazole D III Only one case, failed [229]
Any combination C III Unclear whether combination is more effective
than either drug alone
[6,196,225,230–233]
Liposomal amphotericin B C III Variable activity [96,225]
Amphotericin B deoxycholate D III S. apiospermum may be resistant
Excessive toxicity
[225]
Posaconazole C III Only case reports [234]
Near drowning victims Voriconazole A II Good penetration into central nervous system [89,235–239]
Cystic ﬁbrosis patients Voriconazole B III Therapeutic drug monitoring [227,240,241]
Any combination of antifungals C III Case reports [242,243]
Lung transplantation in cystic
ﬁbrosis patients
First-line therapy
Voriconazole B III Therapeutic drug monitoring [100,102,227,240,244–246]
Salvage therapy
Voriconazole plus caspofungin C III
Caspofungin plus terbinaﬁne C III
Posaconazole C III
Cerebral abscess Voriconazole A III Surgery if possible
Good central nervous system penetration
[236–238]
Any combination C III Unclear [247–249]
Haematopoietic stem cell
transplantation
Neutropenic patients
Chronic granulomatous disease
Granulocyte transfusion
combined with antifungals
C III Independent protective factor, lack of solid data [130,250–252]
Osteomycelitis and/or soft tissue
infections
Surgical debridement plus
antifungals
A III Case reports only [253–257]
Immunocompromised patients Surgical debridement A III Surgical drainage and debridement of necrotic tissues
is essential to the success of therapy
[96,258,259]
QoE, quality of evidence; SoR, strength of recommendation.
TABLE 9. Summary of recommendations for treatment of Scedosporium proliﬁcans infection
Population Intention SoR QoE Comment References
Immunocompromised patients Voriconazole A IIt,r 40% survival Therapeutic drug monitoring [96,260,261]
Lung infections Voriconazole plus terbinaﬁne B III Case reports, 50% survival [68,91,131,133,262–269]
Itraconazole C III Case reports, 15% survival [97,129,263,270]
Amphotericin B deoxycholate D III Case reports, 4% survival [118,271–276]
Any combination C III Case reports only [86,119,130,277–281]
Fluconazole D III Case reports [98,263,275]
Voriconazole or Posaconazole plus terbinaﬁne
(plus granulocyte colony-stimulating factor)
B III Case reports [68,131,269]
Dissemination Voriconazole B II [261]
Voriconazole plus terbinaﬁne or posaconazole B III Review of case series [68,261,267,282]
Skin and subcutaneous infections Surgery A III [119,283]
Skin and subcutaneous infections Voriconazole B II 91% success rate [261]
Cerebral abscess Surgery plus antifungals A III Improved outcome with voriconazole-
itraconazole failed
[251,284]
Osteomyelitis/septic arthritis Voriconazole B III Extensive surgical debridement enhances
recovery rates; one case even without
antifungals
[261,285]
Fluconazole D III [275]
Combination of voriconazole and terbinaﬁne
or caspofungin
B III [111,132,286]
Surgery A III [111,119,251,275,282,285,286]
QoE, quality of evidence; SoR, strength of recommendation.
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have reviewed the genus and some species of clinical interest
have been transferred to the genera Sarocladium and Gliomastix.
Species that have been reported to cause infections in humans
are Acremonium alabamensis, Acremonium kiliense (currently
Sarocladium kiliense), Acremonium roseogriseum (currently Glio-
mastix roseogrisea), Acremonium strictum (currently Sarocladium
strictum), Acremonium potronii and Acremonium recifei. Acremo-
nium falciforme is nowadays Fusarium falciforme, a member of
the Fusarium solani species complex. Members of this genus are
recognized as aetiological agents of nail and corneal infections,
mycetoma, peritonitis and dialysis ﬁstula infection, osteomy-
elitis, meningitis following spinal anaesthesia in a healthy
person, cerebritis in an intravenous drug abuser, endocarditis
in a prosthetic valve operation, and a pulmonary infection in a
child [147,149–154]. Occasionally, deep Acremonium infections
have been reported in patients with serious underlying
diseases [8].
The deﬁnitive diagnosis requires isolation of Acremonium
from infected sites (AII) and blood cultures may become
positive only once the disease has progressed. Members of the
genus Acremonium grow slowly; therefore, culture plates need
to be incubated for at least 2 weeks for detection. In vitro,
Acremonium spp. may be susceptible to amphotericin B and the
azoles [8,155,156], Table 1. However, a recent study demon-
strated high MICs for all agents tested, except for terbinaﬁne
[157].
Clinical data on treatment of infections by Acremonium spp.
are limited to case reports, Table 12. Based on the clinical
outcomes observed we recommend treatment with vorico-
nazole (AII), amphotericin B (BII) and posaconazole (BII)
[153,158–160]. Surgery and catheter removal have also been
reported as part of the successful management of these
infections (CIII) [153,161]; however, a standard therapy is
lacking.
Scopulariopsis Infections
Among the human-pathogenic fungi, the genus Scopulariopsis
(teleomorphs in Microascus species) is phylogenetically close
to Scedosporium. Scopulariopsis species are in vitro usually
quite resistant to antifungal agents including itraconazole,
ﬂuconazole and ﬂucytosine and variously susceptible to
amphotericin B, miconazole and ketoconazole [162]. Oral
itraconazole and terbinaﬁne and topical natamycin were
reportedly effective in treating onychomycosis due to this
organisms [163,164].
Scopulariopsis brevicaulis rarely causes human infection and is
the most common species of the genus in clinical specimens.
The deﬁnitive diagnosis requires isolation of Scopulariopsis from
infected sites (AII). In otherwise healthy individuals this
organism has been reported to cause onychomycosis
[163,164], keratitis [165], otomycosis [166], invasive sinusitis
[167] and prosthetic valve endocarditis [168,169] as well as
TABLE 11. Summary of recommendations for treatment of Paecilomyces variotii and Purpureocillium lilacinum infections
Population Intention SoR QoE Comment References
Immunocompromised
patients
Surgery B III Subcutaneous skin infections cure faster with surgery [288–293]
B III P. variotii, deep infections [294]
Amphotericin B deoxycholatea A III 75% cure for P. variotii
athe use of amphotericin B-lipid-preparation is recommended
[142,295,296]
Amphotericin B deoxycholatea and
itraconazole
C III P. variotii; case report: cure [297,298]
Ketoconazole C III P. lilacinum; case report: cure
Obsolete drug when second-generation azoles are available
[292]
Second-line treatment with itraconazole C III P. variotii; case report: cure [295]
Amphotericin B deoxycholate and
5-Fluorocytosine
C III P. lilacinum; case report: cure [299]
Any population (mixed
patients)
Amphotericin B deoxycholatea B IIr Cases and case series. [7,300,301]
Itraconazole P. lilacinum and P. variotii most frequently associated with
cutaneous disease.
Voriconazole P. lilacinum usually susceptible to voriconazole and
posaconazole, but amphotericin B resistant
Posaconazole athe use of amphotericin B-lipid-preparation is recommended
QoE, quality of evidence; SoR, strength of recommendation.
TABLE 10. Indications for surgical removal of tissue infected
with Fusarium and Scedosporium species
Surgical intervention SoR Qoe References
Haemoptysis from a single cavitary lung lesion
(always perform a computerized chest scan to
search for other lesions)
A III [2,5,57–59]
Progressive cavitary lung lesion (always perform a
computerized chest scan to search for other
lesions)
A III [2,5,57–59]
Inﬁltration into the pericardium, great vessels,
bone or thoracic soft tissue
A III [2,5,57–59]
Osteomyelitis, septic arthritis A IIr [2,46,47,155–
159,257,287]
Resection of infected/colonized tissue before
commencing immunosuppressive agents to
prevent dissemination in case of cytotoxic
therapy
A III [2]
QoE, quality of evidence; SoR, strength of recommendation.
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invasive infections in patients with cystic ﬁbrosis [170]. Invasive
infections have been reported among immunocompromised
patients [171]. These infections involve mainly soft tissues and
lungs [172–179] and are associated with a high mortality. The
optimal antifungal treatment has not been established. Invasive
infections may require surgical and medical treatment (AIII);
infections are frequently fatal [172,173,180], Table 13.
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QoE, quality of evidence; SoR, strength of recommendation.
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